181 related articles for article (PubMed ID: 16015034)
1. Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.
Pujade-Lauraine E; Topham C
Oncology; 2005; 68(2-3):122-9. PubMed ID: 16015034
[TBL] [Abstract][Full Text] [Related]
2. Optimising anaemia management with epoetin beta.
Reed N; Morère JF
Oncology; 2004; 67 Suppl 1():12-6. PubMed ID: 15486448
[TBL] [Abstract][Full Text] [Related]
3. Evolving treatment strategies for anaemia in cancer: experience with epoetin beta.
Aapro M; San Miguel J
Oncology; 2004; 67 Suppl 1():17-22. PubMed ID: 15486449
[TBL] [Abstract][Full Text] [Related]
4. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
[TBL] [Abstract][Full Text] [Related]
5. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
[TBL] [Abstract][Full Text] [Related]
6. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
7. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
8. Epoetin versus darbepoetin conundrum compromise.
Bleyer A
J Clin Oncol; 2006 Sep; 24(25):e46. PubMed ID: 16943519
[No Abstract] [Full Text] [Related]
9. Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.
Spaëth D
Expert Rev Anticancer Ther; 2008 Jun; 8(6):875-85. PubMed ID: 18533797
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cancer-related anemia with epoetin alfa: a review.
Ferrario E; Ferrari L; Bidoli P; De Candis D; Del Vecchio M; De Dosso S; Buzzoni R; Bajetta E
Cancer Treat Rev; 2004 Oct; 30(6):563-75. PubMed ID: 15325036
[TBL] [Abstract][Full Text] [Related]
11. Phase III clinical trials with darbepoetin: implications for clinicians.
Glaspy J
Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
[TBL] [Abstract][Full Text] [Related]
13. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
[TBL] [Abstract][Full Text] [Related]
14. Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon).
Glaspy J; Beguin Y
Oncology; 2005; 69 Suppl 2():8-16. PubMed ID: 16244505
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
Heras P; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
[TBL] [Abstract][Full Text] [Related]
16. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks.
Gabrilove JL; Perez EA; Tomita DK; Rossi G; Cleeland CS
Cancer; 2007 Oct; 110(7):1629-40. PubMed ID: 17694552
[TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.
Ichinose Y; Seto T; Nishiwaki Y; Ohe Y; Yamada Y; Takeda K; Saijo N; Hotta T
Jpn J Clin Oncol; 2010 Jun; 40(6):521-9. PubMed ID: 20508073
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
